ProQR Therapeutics N.V.

NASDAQ:PRQR

Biotechnology

Healthcare
$1.10 +12.28%

+$0.21 today

Market cap
$155.23M
Beta
0.06
P/E (TTM)
-3.8
EPS (TTM)
-$0.43
52W Low $1.33High $3.10

Volume 0.88M

Average 0.62M

PRQR EBITDA

Earnings before interest, taxes, depreciation, and amortization; a proxy for operating profit before non-cash and financing charges.

ProQR Therapeutics N.V.NASDAQ: PRQR

EBITDA · Q1 FY2026 · quarter ended Mar 2026

EBITDA remains negative

Q1 FY2026 EBITDA was -€12.9M, compared with -€9.4M a year earlier. Trailing-twelve-month EBITDA was -€42.88M.

Context

  • EBITDA amounted to 242.4% of revenue in FY2025, up 114.8 pp from a year earlier.
  • EBITDA grew in size in 2 of the last 3 fiscal years.

What to watch

Whether EBITDA reaches the consensus estimate from 6 analysts of -€42.8M (-15.5%) for the fiscal year ending Dec 2026, a step up from the -53.5% reported in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
-€12.9M-58.0% QoQ
Last fiscal yearDec 2025
-€37.04M-53.5% YoY
LTMMar 2026
-€42.88M-67.7% YoY
EBITDA past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-37.2%-2.8%+34.4 pp
1 year-53.5%-15.5%+38.0 pp
3-year CAGR———
5-year CAGR——
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

EBITDA history

EUR · from the income statement

Latest · FY2025
(37.04M) EUR
Year-over-year change
-53.5%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

EBITDA vs competitors

How PRQR compares with its peers on the latest reported figures

  • Peers report in different currencies, so EBITDA is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -67.7% is the 9th highest of 11, against a peer median of -9.1%.
  • EBITDA amounts to 319.0% of revenue for PRQR, versus a peer median of 752.6%.
PRQR Competitors
EBITDA for PRQR and competitors
Company Period LTM YoY 3-year CAGR% of revenue
CAPRCapricor Therapeutics, Inc.LTM Mar 2026$893.33M USD+1767.7%——
MREOMereo BioPharma Group plcLTM Mar 2026-$39.29M USD+13.4%—7858.4%
PRQRProQR Therapeutics N.V.LTM Mar 2026-€42.88M EUR-67.7%—319.0%
ACHVAchieve Life Sciences, Inc.LTM Mar 2026-$50.86M USD-14.6%——
IMMPImmutep LimitedFY2025-A$62.88M AUD-41.2%—1246.6%
ARCTArcturus Therapeutics Holdings Inc.LTM Mar 2026-$67.53M USD-3.7%—148.9%
ZURAZura Bio LimitedLTM Mar 2026-$75.38M USD-21.4%——
EDITEditas Medicine, Inc.LTM Mar 2026-$100.08M USD+56.8%—258.7%
VNDAVanda Pharmaceuticals Inc.LTM Mar 2026-$136.24M USD-213.5%—62.6%
ALLOAllogene Therapeutics, Inc.LTM Mar 2026-$160.41M USD+32.7%——
TRDAEntrada Therapeutics, Inc.LTM Mar 2026-$164.87M USD-697.5%—2873.3%
Peer median (excluding PRQR) —-9.1%—752.6%

Competitors are the stored peer set for PRQR. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

EUR
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue1.34M3.59M6.51M18.91M15.28M
Cost of Revenue00002.6M
Gross Profit1.34M3.59M6.51M18.91M12.68M
Gross Margin100.0%100.0%100.0%100.0%83.0%
Research & Development42.22M50.87M25.15M36.36M40.72M
Selling, General & Admin17.37M18.65M16.24M13.66M14.12M
Operating Expenses58.55M68.75M38.37M49.38M54.84M
Depreciation & Amortization2.33M2.52M2.51M2.76M2.6M
EBITDA(54.95M)(56.46M)(24.1M)(24.12M)(37.04M)
EBITDA Margin-4116.0%-1571.0%-369.9%-127.6%-242.4%
Operating Income(57.21M)(65.16M)(31.86M)(30.47M)(42.15M)
Operating Margin-4285.4%-1813.0%-489.1%-161.2%-275.9%
Interest Income5K106K2.59M3.25M2.24M
Interest Expense3.41M5.13M1.2M1.08M866.4K
Other Income / Expenses(3.47M)1.05M4.05M2.51M1.65M
Income Before Tax(60.68M)(64.11M)(27.81M)(27.96M)(40.5M)
Pre-Tax Margin-4545.5%-1783.8%-427.0%-147.9%-265.1%
Income Tax Expense117K96K(78K)(197K)18.25K
Net Income(60.74M)(64.42M)(28.12M)(27.76M)(40.52M)
Net Margin-4549.8%-1792.5%-431.7%-146.9%-265.2%
EPS (Basic)(0.96)(0.91)(0.35)(0.34)(0.38)
EPS (Diluted)(0.96)(0.91)(0.35)(0.34)(0.38)
Weighted Avg Shares64.18M71.64M81.01M81.67M105.33M
Weighted Avg Shares (Diluted)64.18M71.64M81.01M81.67M105.33M

ProQR Therapeutics N.V.

NASDAQ:PRQR

Intrinsic Alpha fair value

Locked

Current Price

$1.10

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.